Pfizer is expecting initial data for use of its Covid-19 vaccine in 2- to 5-year-olds in the fourth quarter of 2021, the company's chief scientific officer Dr. Mikael Dolsten said in prepared remarks ahead of a Tuesday earnings call.
Pfizer is also projecting that there will be an initial data readout for use of its vaccine in children ages 6 months to 2 years old in the first quarter of 2022.
Pfizer has projected US Food and Drug Administration emergency use authorization for the vaccine in 2- to 5-year-olds in the first half of 2022, and for children ages 6 months to 2 years old in the second half of the year.
The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is meeting today to discuss Pfizer’s Covid-19 vaccine for children ages 5 to 11. Once ACIP makes a recommendation on the use of the vaccine and the CDC director signs off, shots can start to be administered.